Quick summary: PT-141 (bremelanotide) is a 7-amino-acid peptide and selective melanocortin-4 receptor (MC4R) agonist approved by the FDA as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike Viagra-class drugs, which increase blood flow, PT-141 works centrally on the brain to increase sexual arousal and desire. Administered as a subcutaneous injection 45 minutes before sexual activity. Clinical evidence shows significant improvement in satisfying sexual events compared to placebo. Side effects include nausea, facial flushing and potential skin darkening.
PT-141, the generic name for bremelanotide, is a synthetic heptapeptide (7-amino-acid sequence) developed as a treatment for sexual dysfunction. The FDA approved it in 2019 under the brand name Vyleesi specifically for premenopausal women with hypoactive sexual desire disorder (HSDD). It is a peptide hormone with a fundamentally different mechanism than the phosphodiesterase inhibitors (Viagra, Cialis) that dominate sexual dysfunction treatment.
PT-141 is related structurally to melanotan-2, another melanocortin agonist, but with different tissue specificity and clinical applications. While melanotan-2 was initially studied for erectile dysfunction and tanning, PT-141 was specifically optimised for the arousal and desire pathway in women, leading to the focused HSDD indication.
Research context: PT-141 development involved Palatin Technologies, and the compound sat in clinical development for over a decade before the FDA approval of Vyleesi in 2019. The DESIRE (female sexual desire) clinical trial programme drove regulatory approval.
PT-141 works as a selective agonist of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor expressed in the hypothalamus and other brain regions involved in sexual motivation and arousal. This is a central nervous system mechanism - it does not primarily alter genital blood flow, which is why it is categorically different from phosphodiesterase inhibitors.
The melanocortin pathway is ancient and multifunctional - it regulates appetite, energy homeostasis, immune signalling, and sexual behaviour. Activation of MC4R in the ventromedial hypothalamus and dorsomedial hypothalamus increases sexual motivation in animal models and appears to increase subjective sexual arousal and desire in humans.
This peptide specificity for the MC4R (rather than broad melanocortin receptor activation) reduces off-target effects like systemic pigmentation, though skin darkening remains a documented side effect in a subset of users.
PT-141's path to approval was the DESIRE trial programme - a set of Phase 3 randomised controlled trials in premenopausal women with HSDD. The primary endpoint was increase in satisfying sexual events per month, a patient-reported outcome measure distinct from mechanistic surrogates.
Trial design snapshot: Women were randomised to placebo or PT-141 (tested at 0.75 mg and 1.75 mg doses). The trials showed statistically significant improvement in sexual desire, sexual arousal, and the primary outcome of satisfying sexual events per month compared to placebo. Effect sizes were modest (typically a 1-2 event-per-month increase in the treatment arms), but consistent.
The nausea rate in the trials was notable - 25-40% depending on dosing arm, leading to dose-dependent tolerability considerations. Blood pressure elevations were also observed and required monitoring. The trials enrolled hundreds of participants and lasted several months, providing a reasonable evidence base for the HSDD indication in women.
It is important to note that Vyleesi's FDA approval is restricted to premenopausal women with HSDD. Off-label use in men or postmenopausal women is outside the regulatory approval and carries unknown risk/benefit profiles. The clinical evidence does not extend to those populations.
The comparison is mechanistic, not clinical:
A key difference: PDE5 inhibitors improve the mechanics of sexual response (blood flow, erection); PT-141 enhances the motivation and desire for sexual activity. They address different physiological systems. Combined use is theoretically possible but clinical data is sparse. In clinical practice, some prescribers have explored combination therapy for patients who respond partially to one agent alone.
The FDA-approved form of PT-141 (Vyleesi) is a subcutaneous injection, not a nasal spray. Patients self-administer 0.75 mg or 1.75 mg via a prefilled autoinjector 45 minutes before anticipated sexual activity. Dosing more than once per 24 hours is not recommended.
Nasal spray formulations of PT-141 and related melanocortin agonists have been studied in research, and some ongoing clinical trials or compounded preparations may use intranasal administration. However, online marketing claims about "PT-141 nasal spray" should be viewed with caution - these are typically not FDA-approved products and their purity, stability and dose accuracy are unverified.
Formulation red flag: If you encounter PT-141 marketed as a nasal spray at a non-medical e-commerce site, the product is either research-stage compound (unregulated) or misrepresented. The approved pharmaceutical product is injectable only.
PT-141's adverse event profile from clinical trials:
Contraindications and cautions include uncontrolled hypertension, coronary artery disease, and concurrent use of strong CYP3A4 inhibitors. Pregnancy is a clear contraindication (the indication is premenopausal HSDD, but contraception is required). Renal and hepatic impairment may affect tolerability.
From a research perspective, PT-141 is valuable as a tool to study melanocortin signalling in sexual behaviour and motivation. The MC4R is a well-validated target in rodent models of sexual function, and PT-141's approval provides clinical confirmation that central melanocortin activation can modulate human sexual desire in women.
Ongoing research areas include:
Is PT-141 the same as melanotan-2?
No. Both are melanocortin agonists, but PT-141 (bremelanotide) is a 7-amino-acid peptide optimised for sexual desire in women, while melanotan-2 is a larger, less selective compound originally studied for tanning and erectile dysfunction. PT-141 has FDA approval; melanotan-2 does not.
Can I use PT-141 if I am on blood pressure medication?
PT-141 itself can raise blood pressure. Use with antihypertensive drugs requires medical supervision and monitoring. Do not self-prescribe.
How quickly does PT-141 work?
The subcutaneous injection is absorbed over 30-45 minutes, with peak effects around 45 minutes. Sexual activity is typically anticipated for that window. The duration of effect is a few hours at most.
Can PT-141 be used daily?
No - Vyleesi is dosed on-demand, 45 minutes before sexual activity, no more than once per 24 hours. It is not a daily maintenance therapy.
Does PT-141 work better than Viagra for women?
The clinical indications are different - Viagra addresses erectile dysfunction mechanisms in men and some women; PT-141 addresses desire/arousal disorder specifically. "Better" depends on the underlying physiology. Some women may benefit from PT-141 if their primary concern is desire; others may respond better to vascular agents if flow is the limiting factor.
External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way. This article is general educational information, not medical advice.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog